<address id="5b7vh"><nobr id="5b7vh"></nobr></address>

          <address id="5b7vh"><dfn id="5b7vh"><mark id="5b7vh"></mark></dfn></address>
          <sub id="5b7vh"></sub>
          <address id="5b7vh"><listing id="5b7vh"><menuitem id="5b7vh"></menuitem></listing></address>

            <address id="5b7vh"></address>

            首頁 雜志概況 投稿須知 在線投稿 在線閱讀 征訂啟事 廣告服務 行業資訊 企業動態 資料中心  專訪報道 會展信息 ENGLISH

            引用本文:   郭佳, 劉金華, 楊照微, 李毅, 何成彥. 基于二級質譜數據的非標記定量人腎透明細胞癌組織蛋白質組學研究. 分析化學, 2020, 48(10): 1351-1358. doi:  10.19756/j.issn.0253-3820.201373 [復制]

            Citation:   GUO Jia , LIU Jin-Hua , YANG Zhao-Wei , LI Yi , HE Cheng-Yan . Proteomics Analysis of Human Renal Clear Cell Carcinoma by Two MS2-based Label-free Approaches. Chinese Journal of Analytical Chemistry, 2020, 48(10): 1351-1358. doi: 10.19756/j.issn.0253-3820.201373 [復制]

            基于二級質譜數據的非標記定量人腎透明細胞癌組織蛋白質組學研究

            通訊作者:  李毅, lyi99@jlu.edu.cn; 何成彥, cyhe@jlu.edu.cn

            收稿日期: 2020-06-27

            基金項目: 本文系國家自然科學基金項目(No.81572082)和吉林省科學技術廳基金項目(No.20190201215JC)資助

            Proteomics Analysis of Human Renal Clear Cell Carcinoma by Two MS2-based Label-free Approaches

            Corresponding author:  LI Yi , lyi99@jlu.edu.cn; HE Cheng-Yan , cyhe@jlu.edu.cn

            Received Date:  2020-06-27

            Fund Project:  This work was supported by the National Nature Science Foundation of China (No. 81572082) and the Project of Jilin Province Science and Technology Department (No. 20190201215JC).

            晚期腎癌的化學療法或放射療法效果均不佳,缺少有效的診療分子靶標和治療手段。本研究基于二級質譜(MS2)數據的非標記定量蛋白質組學方法,對晚期腎透明細胞癌和對應的腎臟正常組織樣本進行了蛋白質組學分析,共鑒定出2406個蛋白質。采用譜圖計數和MS2總離子流(Total ion current,TIC)兩種數據處理方法,對蛋白質組學鑒定結果數據進行定量分析。結果表明,MS2總離子流方法可篩選出144個差異蛋白,譜圖計數方法篩選出120個差異蛋白,MS2總離子流方法優于譜圖計數方法。兩種方法共篩選出147個差異蛋白。其中,腫瘤組織上調蛋白有46個,包括膜聯蛋白A4、層粘連蛋白α-4亞基、丙酮酸激酶、ATP-檸檬酸合成酶、組蛋白H1.5和碳酸酐酶9等;下調蛋白有101個,包括電子轉移黃素蛋白β亞基、3-酮脂?;鵆oA硫解酶、絨毛蛋白-1、V型質子ATP合成酶F亞基、線粒體磷酸鹽載體蛋白、細胞色素b-c1復合物8亞基、多重耐藥抗性蛋白1、視黃醛脫氫酶2和尿調蛋白等。使用MS1數據對部分差異蛋白分析結果進行了相互驗證。本研究基于MS2數據的非標記定量分析研究方法,對腎透明細胞癌組織進行蛋白質組學分析,篩選出的差異蛋白可作為腎透明細胞癌診治、預后判斷的候選標志物,為尋找晚期腎透明細胞癌有效的治療靶點提供了基礎數據。

            關鍵詞:   蛋白質組, 譜圖計數, 二級質譜總離子流, 非標記定量, 腎透明細胞癌
            Key words:   Proteomics, Spectral count, MS2 total ion current, Label-free quantification, Renal clear cell carcinoma
            [1]

            Linehan W M, Ricketts C J. Nat. Rev. Urol., 2019, 16(9):539-552

            [2]

            Lalani A A, McGregor B A, Albiges L, Choueiri T K, Motzer R, Powles T, Wood C, Bex A. Eur. Urol., 2019, 75(1):100-110

            [3]

            Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo R G, Kolenko VM. Mol. Cancer Ther., 2018, 17(7):1355-1364

            [4]

            Yang W, Shi J, Zhou Y, Liu T, Li J, Hong F, Zhang K, Liu N. Proteomics Clin. Appl., 2019, 13(6):e1900017

            [5]

            Sun N, Wang Y, Wang J, Sun W, Yang J, Liu N. Anal. Chem., 2020, 92(12):8292-8297

            [6]

            Uzawa K, Kasamatsu A, Saito T, Kita A, Sawai Y, Toeda Y, Koike K, Nakashima D, Endo Y, Shiiba M, Takiguchi Y, Tanzawa H. Exp. Cell Res., 2019, 376(2):210-220

            [7]

            Yuan X L, Zhang P, Liu X M, Du Y M, Hou X D, Cheng S, Zhang Z F. Sci. Rep., 2017, 7:12572

            [8]

            Diaz-Montero C M, Mao F J, Barnard J, Parker Y, Zamanian-Daryoush M, Pink J J, Finke J H, Rini B I, Lindner D J. Br. J. Cancer, 2016, 115(8):920-928

            [9]

            Kim D I, Cutler J A, Na C H, Reckel S, Renuse S, Madugundu AK, Tahir R, Goldschmidt H L, Reddy K L, Huganir R L, Wu X, Zachara N E, Hantschel O, Pandey A. J. Proteome Res., 2018, 17(2):759-769

            [10]

            Yang W, Shi J, Zhou Y, Liu T, Zhan F, Zhang K, Liu N. Int. J. Oncol., 2019, 55(2):439-450

            [11]

            Raimondo F, Pitto M. Expert Rev. Proteomics, 2020, 17(4):323-334

            [12]

            Creighton C J. Nat. Rev. Nephrol., 2020, 16(3):133-134

            [13]

            Zhao C, Chen J, Ling Y, Wang S. J. Cell. Biochem., 2019, 120(6):9506-9513

            [14]

            Liu J, Hanavan P D, Kras K, Ruiz Y W, Castle E P, Lake D F, Chen X, O'Brien D, Luo H, Robertson K D, Gu H, Ho T H. J. Proteome Res., 2019, 18(1):331-340

            [15]

            Gomig T H B, Cavalli I J, Souza R LR, Vieira E, Lucena A C R, Batista M, Machado K C, Marchini F K, Marchi F A, Lima R S, de Andrade Urban C, Cavalli L R, Ribeiro E M S F. J. Proteomics, 2019, 199:1-14

            [16]

            Le Faouder J, Gigante E, Léger T, Albuquerque M, Beaufrère A, Soubrane O, Dokmak S, Camadro JM, Cros J, Paradis V. Proteomics Clin. Appl., 2019, 13(1):e1800128

            [17]

            Choi Y, Jeong K, Shin S, Lee J W, Lee Y S, Kim S, Kim S A, Jung J, Kim K P, Kim V N, Kim J S. Anal Chem., 2020, 92(7):4980-4989

            [18]

            Branson O E, Freitas M A. J. Proteomics, 2016, 144:23-32

            [19]

            Spinelli K J, Klimek J E, Wilmarth P A, Shin J B, Choi D, David L L, Gillespie P G. Proc. Natl. Acad. Sci. USA, 2012, 109(5):E268-E277

            [20]

            Eng J K, Jahan T A, Hoopmann M R. Proteomics, 2013, 13(1):22-24

            [21]

            Robinson M D, McCarthy D J, Smyth G K. Bioinformatics, 2010, 26(1):139-140

            [22]

            MacLean B, Tomazela D M, Shulman N, Chambers M, Finney G L, Frewen B, Kern R, Tabb D L, Liebler D C, MacCoss M J. Bioinformatics, 2010, 26(7):966-968

            [23]

            Arya R, Dabral D, Faruquee H M, Mazumdar H, Patgiri S J, Deka T, Basumatary R, Kupa R U, Semy C, Kapfo W, Liegise K, Kaur I, Choedon T, Kumar P, Behera R K, Deori P, Nath R, Khalo K, Saikia L, Khamo V, Nanda R K. Proteomics Clin. Appl., 2020, 14(1):e1900062

            [24]

            Marín-Vicente C, Mendes M, de Los Ríos V, Fernández-Aceñro M J, Casal J I. Proteomics Clin. Appl., 2020, 14(1):e1900052

            [25]

            Wei B, Guo C, Liu S, Sun M Z. Clin. Chim. Acta, 2015, 447:72-78

            [26]

            Rocha M R, Barcellos-de-Souza P, Sousa-Squiavinato A C M, Fernandes P V, de Oliveira I M, Boroni M, Morgado-Diaz J A. Sci. Rep., 2018, 8:11285

            計量
            • PDF下載量(60)
            • 文章訪問量(144)
            • HTML全文瀏覽量(2)

            目錄

            基于二級質譜數據的非標記定量人腎透明細胞癌組織蛋白質組學研究

            郭佳, 劉金華, 楊照微, 李毅, 何成彥

            Figures and Tables

            168彩票